Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitex Takes On Baxter: Will Parallel Study Favor Swift Inactine Approval?

This article was originally published in The Gray Sheet

Executive Summary

A parallel arm design for Vitex' Phase III pivotal trial testing the Inactine red blood cell pathogen inactivation system in chronic anemia patients positions Vitex to be the first to market in the U.S., according to the firm

You may also be interested in...



Pall Retains Inactine U.S. Marketing Option Under Altered Terms With Vitex

Pall Corp. will decide at the end of one year whether to revert to exclusive U.S. marketing rights for Vitex' Inactine red blood cell pathogen reduction system

Pall Retains Inactine U.S. Marketing Option Under Altered Terms With Vitex

Pall Corp. will decide at the end of one year whether to revert to exclusive U.S. marketing rights for Vitex' Inactine red blood cell pathogen reduction system

Baxter, Cerus Enter $120 Mil. Platelet Market With EU Intercept Approval

Baxter and Cerus plan to launch the first pathogen inactivation system for blood platelets by October, pending widespread blood bank validations and CE mark of a companion device

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel